{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated/Withdrawn" in comments (approximate match)
Status:
Investigational
Source:
NCT01638936: Phase 1/Phase 2 Interventional Completed Multiple Myeloma
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02452554: Phase 2 Interventional Completed Pleuropulmonary Blastoma
(2015)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT02573324: Phase 3 Interventional Completed Glioblastoma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02324049: Phase 1/Phase 2 Interventional Completed Mucopolysaccharidosis IIIB
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00072930: Phase 2 Interventional Completed Prostate Cancer
(2003)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01123083: Phase 3 Interventional Completed Diabetes Mellitus, Type 1
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:lusacomfar alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00004806: Phase 1 Interventional Completed Cystic Fibrosis
(1995)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04209114: Phase 3 Interventional Completed Bladder Cancer
(2020)
Source URL:
Class:
PROTEIN
